Abuse liability measures for use in analgesic clinical trials in patients with pain: IMMPACT recommendations
| Autor: | Sharon Hertz, Michael Klein, Gary M. Reisfield, James P. Zacny, George E. Bigelow, Laurie B. Burke, Shannon M. Smith, Robert D. Colucci, Ernest A. Kopecky, Sharon L. Walsh, Cristina Sampaio, Srinivasa N. Raja, Robert L. Balster, Richard A. Denisco, John T. Farrar, Edgar H. Adams, Edward J. Cone, Bob A. Rappaport, Deborah B. Leiderman, Pamela Palmer, Beatrice Setnik, Sandra D. Comer, Dennis C. Turk, Nathaniel P. Katz, Penney Cowan, Jennifer A. Haythornthwaite, Richard W. Foltin, Joseph W. Stauffer, Michael P. McDermott, Michael C. Rowbotham, Kelly Posner, Robert H. Dworkin, Marta Sokolowska, Alec B. O'Connor, Charles A. O'Brien, Christine Rauschkolb, J. David Haddox, Roderick Junor, Gary W. Jay |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
medicine.medical_specialty
Active Comparator business.industry Addiction media_common.quotation_subject Alternative medicine Placebo law.invention Clinical trial Anesthesiology and Pain Medicine Neurology Randomized controlled trial Pain assessment law Physical therapy Medicine Neurology (clinical) business Adverse effect Psychiatry media_common |
| Zdroj: | Pain. 154:2324-2334 |
| ISSN: | 0304-3959 |
| DOI: | 10.1016/j.pain.2013.06.035 |
| Popis: | Assessing and mitigating the abuse liability (AL) of analgesics is an urgent clinical and societal problem. Analgesics have traditionally been assessed in randomized clinical trials (RCTs) designed to demonstrate analgesic efficacy relative to placebo or an active comparator. In these trials, rigorous, prospectively designed assessment for AL is generally not performed. The Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) convened a consensus meeting to review the available evidence and discuss methods for improving the assessment of the AL of analgesics in clinical trials in patients with pain. Recommendations for improved assessment include: (1) performing trials that include individuals with diverse risks of abuse; (2) improving the assessment of AL in clinical trials (eg, training study personnel in the principles of abuse and addiction behaviors, designing the trial to assess AL outcomes as primary or secondary outcome measures depending on the trial objectives); (3) performing standardized assessment of outcomes, including targeted observations by study personnel and using structured adverse events query forms that ask all subjects specifically for certain symptoms (such as euphoria and craving); and (4) collecting detailed information about events of potential concern (eg, unexpected urine drug testing results, loss of study medication, and dropping out of the trial). The authors also propose a research agenda for improving the assessment of AL in future trials. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|